Antibodies

16 Sep 2017 New Two-Year TREMFYA™ (guselkumab) Data Show Patients With Moderate To Severe Plaque Psoriasis Achieved Consistent Rates Of Skin Clearance
16 Sep 2017 Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
16 Sep 2017 Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
15 Sep 2017 CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
15 Sep 2017 Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®
15 Sep 2017 Samsung Bioepis First to Receive Positive CHMP Opinion on a Trastuzumab Biosimilar with ONTRUZANT®
14 Sep 2017 FDA approves first biosimilar for the treatment of cancer
14 Sep 2017 Levicept Starts First-in-Human Phase I Trial of LEVI-04, A Novel Fusion Protein Therapy for Chronic Pain
14 Sep 2017 Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab)
14 Sep 2017 LEO Pharma announces more than half of patients on Kyntheum® (brodalumab) maintain consistent levels of complete skin clearance for more than two years
14 Sep 2017 Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
13 Sep 2017 OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial
13 Sep 2017 ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer's Disease
13 Sep 2017 Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
12 Sep 2017 Sandoz proposed biosimilar rituximab accepted for review by the FDA
11 Sep 2017 Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
11 Sep 2017 Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer
11 Sep 2017 Merck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
11 Sep 2017 Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress
11 Sep 2017 BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress
11 Sep 2017 Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Phase 3 Trial in Uncontrolled Persistent Asthma
11 Sep 2017 Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study
11 Sep 2017 Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate -214 Trial
10 Sep 2017 Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
10 Sep 2017 Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at ESMO Congress 2017

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top